GC Cell Corporation (144510:KOSDAQ), fully integrated company involved in cell and gene therapy and a subsidiary of Korean-listed pharmaceutical group GC Biopharma Corp, announced on Sunday that it entered into an international strategic cooperation agreement with Lukas Biomedical Co., Ltd (TWSE 6814), a Taiwan-based biomedical company, specialising in immune cell cultures.
The partnership is aimed at raising awareness of autologous T cell therapy and to expand the patient access market by using each other's strengths in innovative cell treatment areas. Both companies aim to accelerate drug development and establish a platform for precision medicine solutions by sharing research projects, clinical trial data, regulatory knowledge across multiple countries, and exploring clinical research, market development and various activities for cancers and other challenging diseases. The collaboration aims to bring the benefits of innovative cell therapy to a wider range of patients.
James Park, GC Cell CEO, said, 'This strategic cooperation agreement represents a pivotal milestone in accelerating the advancement of innovative cell therapies in Korea and Taiwan and also in establishing global network and ecosystem of Cell and Gene Therapy. Looking ahead, we are committed to accelerating the global expansion of Immuncell-LC through the continuous exchange of clinical research data and the establishment of a strong, long-term partnership between our two companies.'
Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial
Camurus' Oczyesa recommended for European regulatory approval for acromegaly treatment
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Johnson & Johnson reports TAR-200 monotherapy study data in bladder cancer
CHMP backs Camurus' Oczyesa for acromegaly treatment in EU
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Guardant Health and Pfizer enter global collaboration to advance cancer therapy development
Sanofi invests EUR15m in Innate Pharma to strengthen strategic partnership
Adcendo to present clinical stage ADC data at 2025 AACR Annual Meeting
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older